These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8891737)
41. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551 [TBL] [Abstract][Full Text] [Related]
42. Maintenance immunosuppression therapy and outcome of renal transplantation in North American children--a report of the North American Pediatric Renal Transplant Cooperative Study. Tejani A; Stablein D; Fine R; Alexander S Pediatr Nephrol; 1993 Apr; 7(2):132-7. PubMed ID: 8476703 [TBL] [Abstract][Full Text] [Related]
43. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. Sheshgiri R; Gustafsson F; Sheedy J; Rao V; Ross HJ; Delgado DH J Heart Lung Transplant; 2009 Nov; 28(11):1193-7. PubMed ID: 19783164 [TBL] [Abstract][Full Text] [Related]
44. The role of HLA matching for cadaveric renal transplants in the cyclosporine era. Hunsicker LG; Held PJ Semin Nephrol; 1992 Jul; 12(4):293-303. PubMed ID: 1410858 [No Abstract] [Full Text] [Related]
45. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients. Wieneke H; Otte B; Lang D; Heidenreich S Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953 [TBL] [Abstract][Full Text] [Related]
46. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Worthington JE; Martin S; Al-Husseini DM; Dyer PA; Johnson RW Transplantation; 2003 Apr; 75(7):1034-40. PubMed ID: 12698094 [TBL] [Abstract][Full Text] [Related]
47. Triple-drug regimen for first kidney transplants in developing countries. Erken U; Erken E; Tansuğ Z; Türkyilmaz R Transplant Proc; 1992 Oct; 24(5):1843. PubMed ID: 1412875 [No Abstract] [Full Text] [Related]
48. 14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring. Torres MI; Luque J; Lorite P; Isla-Tejera B; Palomeque T; Aumente MD; Arizon J; Peña J Hum Immunol; 2009 Oct; 70(10):830-5. PubMed ID: 19638290 [TBL] [Abstract][Full Text] [Related]
49. Is sensitivity to cyclosporine influenced by the HLA-DR phenotype of kidney graft recipients? Kyriakopoulos G; Antoniadis A; Gakis D; Papanikolaou V Transplant Proc; 1996 Dec; 28(6):3294-5. PubMed ID: 8962278 [No Abstract] [Full Text] [Related]
50. Kidney function in cyclosporine-treated pediatric heart transplant recipients. Laine J; Jalanko H; Leijala M; Sairanen H; Holmberg C J Heart Lung Transplant; 1997 Dec; 16(12):1217-24. PubMed ID: 9436133 [TBL] [Abstract][Full Text] [Related]
51. A significant role for anti-human leukocyte antigen antibodies and antibody-mediated rejection in the biopsy-for-cause population. Banasik M; Kościelska-Kasprzak K; Myszka M; Bartoszek D; Zabińska M; Boratyńska M; Kamińska D; Mazanowska O; Zmonarski S; Krajewska M; Hałoń A; Dawiskiba T; Nowakowska B; Klinger M Transplant Proc; 2014 Oct; 46(8):2613-7. PubMed ID: 25380878 [TBL] [Abstract][Full Text] [Related]
52. Antibodies against MICA antigens and kidney-transplant rejection. Zou Y; Stastny P; Süsal C; Döhler B; Opelz G N Engl J Med; 2007 Sep; 357(13):1293-300. PubMed ID: 17898098 [TBL] [Abstract][Full Text] [Related]
54. Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibility antigen mismatches. Gerrits JH; van de Wetering J; Postma S; Drabbels JJ; Vaessen LM; IJzermans JN; Rischen J; Claas FH; Weimar W; van Besouw NM Nephrol Dial Transplant; 2007 Feb; 22(2):353-61. PubMed ID: 17124279 [TBL] [Abstract][Full Text] [Related]
55. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients. Câmara NO; Dias MF; Pacheco-Silva A Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825 [TBL] [Abstract][Full Text] [Related]
56. Immunosuppression in live-related donor renal transplantation. Iman A; Rao M; Juneja R; Jacob CK Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322 [TBL] [Abstract][Full Text] [Related]
57. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Borghi A; Fogli E; Stignani M; Melchiorri L; Altieri E; Baricordi O; Rizzo R; Virgili A Arch Dermatol Res; 2008 Nov; 300(10):551-9. PubMed ID: 18797896 [TBL] [Abstract][Full Text] [Related]
58. Quality of serological donor HLA typing: analysis of graft survival by HLA in renal transplantation recipients treated with cyclosporine. Thorogood J; Schreuder GM; Persijn GG; van Rood JJ Transplant Proc; 1992 Dec; 24(6):2485-7. PubMed ID: 1465839 [No Abstract] [Full Text] [Related]
59. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Fernández-Fresnedo G; Pastor JM; López-Hoyos M; Ruiz JC; Zubimendi JA; Gonzalez-Cotorruelo J; Rodrigo E; De Francisco AL; Arias M Nephrol Dial Transplant; 2003 May; 18(5):990-5. PubMed ID: 12686676 [TBL] [Abstract][Full Text] [Related]
60. Association of soluble human leukocyte antigen-G with acute tubular necrosis in kidney transplant recipients. Krongvorakul J; Kantachuvesiri S; Ingsathit A; Rattanasiri S; Mongkolsuk T; Kitpoka P; Thammanichanond D Asian Pac J Allergy Immunol; 2015 Jun; 33(2):117-22. PubMed ID: 26141032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]